Why Don't Patients With Pain Become Addicted to Morphine?

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 10
Volume 5
Issue 10

GLASGOW-Pain specialists continually stress the message that clinicians should not fear prescribing adequate doses of opioids for pain patients, since such patients are not at risk of becoming "addicted."

GLASGOW-Pain specialists continually stress the message that cliniciansshould not fear prescribing adequate doses of opioids for painpatients, since such patients are not at risk of becoming "addicted."

Now a study from the University of Glasgow confirms what painspecialists intuitively know: Pain patients do not become psychologicallydependent on drugs because they are taking narcotics to relievetheir pain and for no other reason; drug abusers, on the otherhand, use narcotics strictly for mood alteration or to inducesleep.

The researchers surveyed three groups who were receiving narcotics:cancer pain patients (14 subjects), patients with chronic nonmalignantpain (27 subjects), and drug addicts enrolled in a methadone maintenanceprogram (30 subjects).

The cancer pain patients had been using opioids for a mean of6 months; the chronic pain patients for 2.2 years; and the drugabusers for 13 years. Median daily morphine equivalent doses weremuch higher in the cancer patients (1,320 mg) than in the chronicpain patients (700 mg) or the drug abusers (160 mg).

Patients' drug use and reasons for varying the dose were recordeddaily for a week, then weekly for a month, then once monthly for3 months, via structured questionnaires and semi-structured interviews,Dr. Marie Fallon, of the Division of Palliative Medicine, reportedin a poster session at the 8th World Congress on Pain in Vancouver.

The results showed that pain patients are not psychologicallydependent on strong opioids. "They have a need to use themfor pain, and when that pain isn't there, they basically don'tneed them," Dr. Fallon said.

The cancer pain patients reported taking extra opioids when theirpain was poorly controlled, and the chronic pain patients saidthey took extra doses when pain was more distressing, but, Dr.Fallon said, the drug abusers' use of extra narcotics beyond whatthey were getting in the maintenance program appeared to be basedon drug availability.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content